DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20190070

Primary antiphospholipid syndrome in children: experience from two tertiary centres in South India

Mahesh Janarthanan, Dhaarani Jayaraman, Julius Scott, M. S. Latha, Saravanan Margabandhu, Chitra Sundaramoorthy, S. Srinivas

Abstract


Background: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the presence of episodes of vascular thrombosis, recurrent fetal loss and other clinical features in the presence of antiphospholipid antibodies. The aim of the study was to analyze the clinical manifestations and immunologic profile of children presenting with APS.

Methods: Authors did a retrospective case record study of patients admitted with thrombotic events between September 2013 and August 2018 and identified patients with positive antiphospholipid antibodies. Children who had clinical features of active lupus were not included.

Results: The clinical and immunologic profile of 7 pediatric patients presenting with APS over 5 years from 2013 to 2018 were analysed. Symptoms secondary to vascular thrombosis were limb swelling, stroke, gangrene of toes and Budd Chiari syndrome.

Conclusions:APS though rare should be considered in the differential diagnosis of children presenting with thrombotic events. They need long term anticoagulants to prevent further episodes.

 


Keywords


Children, Primary antiphospholipid syndrome, Thrombosis

Full Text:

PDF

References


Berkun Y, Kenet G. Pediatric antiphospholipid syndrome. IMAJ. 2008;10:45-7.

Cimaz R, Descloux E. Pediatric antiphospholipid syndrome. Rheum Dis Clin North Am. 2006;32:553-73.

Meroni PLM, Borghi O, Raschi E, Tedescoet F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7:330-9.

Aguiar CL, Soybilgic A, AvcinT, Myones BL. Pediatric antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17:27.

Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530-4.

Go´mez-Puerta JA, Martı´n H, Amigo MC, Aguirre MA, Camps MT, Cuadrado MJ, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome. Do they develop lupus?. Med. 2005;84(4):225-30.

Berkun Y, Padeh S, Barash J, Uziel Y, Harel L, Mukamel M, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheumatism. 2006;55(6):850-5.

Ahluwalia J, Singh S, Naseem S, Suri D, Rawat A, Gupta A, et al. Antiphospholipid antibodies in children with systemic lupus 3 erythematosus: a long-term clinical and laboratory follow-up 4 status study from northwest India. Rheumatol Int. 2014;34:669-73.

Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheumatism. 2002;46(4):1019-27.

Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M, a Garay S, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an International registry. Pediatr. 2008;122(5):e1100-7.

Espinosa G, Font J, Garcia-Pagan JC, TÀssies D, Reverter JC, Gaig C, et al. Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients. Med. 2001;80(6):345-54.

Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017:1-5.